Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors

Inclusion Criteria:

• 1. Age ≥18 years, both sexes; 2) Confirmed by the following diagnostic criteriaCLL/SLL: relapsed or refractory chronic lymphocytic leukemia/small lymphocyticlymphoma confirmed by flow cytometry or histopathology according to iwCLL2018 criteriaMCL: Recurrent or refractory mantle cell lymphoma histopathologically confirmed:including cytogenetic testing T (11;14) Mantle cell lymphoma with positive/highimmunohistochemical expression of Cyclin D1 3) Previous treatment withibrutinib/zanubrutinib/or other BTK inhibitors and any of the following conditionswere defined by the investigator as poor tolerance to ibrutinib/zanubrutinib or otherBTK inhibitors: A) Grade ≥2 nonhematologic toxicity lasting >7 days with or withouttreatment; B) any non-hematological toxicity of ≥ grade 3 ; C) Grade 3 neutropeniawith infection or fever; D) Grade 4 hematologic toxicity that persisted until theinvestigator chose to discontinue ibrutinib/ zanubrutinib or other BTK inhibitors dueto toxicity rather than disease progression 4) The investigator-initiated treatmentdecision to use Orelabrutinib (before study enrollment); 5) Life expectancy ≥3 months;

6. The patient or his or her legal representative voluntarily signed written informedconsent

Exclusion Criteria:

• 1. Richter conversion (CLL/SLL) or disease progression during treatment withibrutinib/ zanubrutinib or other BTK inhibitors; 2) Past treatment with Orelabrutinib;

3. Absolute neutrophil ANC<0.75×109/L, platelet PLT<50×109/L; 4) Blood biochemistry:total bilirubin (TBIL) >2 times the upper limit of normal ULN (unless Gilbert syndromeis diagnosed), AST or ALT>2.5× ULN; Serum creatinine (Cr) >1.5×ULN 5) Coagulationfunction: INR and APTT ≤1.5 × ULN; 6) Grade 3 or 4 adverse events related to ongoingunresponded treatment with ibrutinib/ zanubrutinib or other BTK inhibitors 7)Participate in research projects that use interventions outside the scope of routineclinical practice